TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.

Hussein A Tawbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.